PolyMedix, Inc. is an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders. We focus on serious, life threatening, acute disorders which are also significant market opportunities. Using our proprietary computational drug design technology, we have created novel antibiotic compounds and heptagonists. Our lead candidates in each of these programs, i.v. antibiotic candidate PMX-30063 and the anticoagulant antagonist product candidate PMX-60056, are currently in human clinical trials. PMX-30063 began phase I clinical trials in August, 2008 and PMX-60056 began clinical trials in September 2008.